French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002.
about
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational studyCellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in EuropeRecent HIV-1 infection contributes to the viral diffusion over the French territory with a recent increasing frequencyTransmitted antiretroviral drug resistance in New York State, 2006-2008: results from a new surveillance systemFirst line treatment response in patients with transmitted HIV drug resistance and well defined time point of HIV infection: updated results from the German HIV-1 seroconverter studyCharacteristics of HIV-1 natural drug resistance-associated mutations in former paid blood donors in Henan Province, ChinaEstimating trends in the proportion of transmitted and acquired HIV drug resistance in a long term observational cohort in GermanyDevelopment and customization of a color-coded microbeads-based assay for drug resistance in HIV-1 reverse transcriptaseTrends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012)Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysisAnalyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration.Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.HIV Genetic Diversity and Drug Resistance.Consensus drug resistance mutations for epidemiological surveillance: basic principles and potential controversies.Analysis of a local HIV-1 epidemic in portugal highlights established transmission of non-B and non-G subtypesRole of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicideThe Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.New and old complex recombinant HIV-1 strains among patients with primary infection in 1996-2006 in France: the French ANRS CO06 primo cohort study.The challenge of HIV-1 subtype diversity.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Reverse transcriptase inhibitors as potential colorectal microbicides.Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes.Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism.Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008)Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach.Statements from the 15th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), Toulon, France, May 28-30, 2008.Spatiotemporal dynamics of HIV-1 transmission in France (1999-2014) and impact of targeted prevention strategies.Update on antiretroviral treatment during primary HIV infection.Performance of three commercial viral load assays, Versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants.Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial.Development and evaluation of a national reference panel of HIV-1 protease and reverse transcriptase drug-resistance mutations for HIV-1 genotypic resistance assays in China.Impact of HIV-1 Subtype on CD4 Count at HIV Seroconversion, Rate of Decline, and Viral Load Set Point in European Seroconverter CohortsMonitoring HIV drug resistance in treatment-naive individuals: molecular indicators, epidemiology and clinical implicationsHIV-1 nonsubtype B distribution across certain resource-rich countries
P2860
Q24538955-353903F2-1D94-47F7-9727-B346D30BA7D8Q28474278-1C2845E3-46A4-4A31-A4FD-2121E9F132A8Q28480667-476DF877-0BB6-4E9E-A4AE-0A54990F4A15Q28482098-5043A0A8-4E64-4768-87A8-1230C38CC37EQ28538326-DE24F534-B805-49D9-BA65-EE05A507A717Q28539927-7B59DC74-2DBA-46B3-80AF-AD677AE13799Q28542508-9956DE89-CFF8-4F6A-845D-E9F419E8DB04Q28543768-6E4C4560-4325-425A-9B27-9D859045FA7DQ28547790-5D45E57A-D29B-468B-B70C-87ED45FB4056Q33459535-852E9E86-3DB6-419C-9279-2AEA98B9F4DAQ33972150-73B7DE28-F2A5-41B8-8769-821EDEC8F369Q33988153-96ACE71E-B70A-4662-90F8-8E9DE5DD0F88Q34087809-0D509986-0CC3-434D-AE94-065576880CE6Q34885660-1F5D2CF9-0676-4E71-A5F4-5BB534294136Q34923677-2B55B778-7D5B-4F58-A55E-DC9D22B5A97BQ35260403-1791F9EF-6952-48D5-96D4-F4D4A5ACAB5CQ35260590-0F2E7EFC-0C23-410D-AF2B-1DDB9247A4ABQ35300021-09117D5C-18AF-4DBC-BA4C-1B44EB496ACCQ35455551-739369E5-40F6-4780-801D-941B59FB7A78Q35557235-377CE30B-45A6-4B78-AEBD-68224D83F2C9Q35941336-531A58FE-259D-4200-AE1E-EF2A34F24AD8Q36077418-82FBF7AB-6866-43FC-AF07-EBFA4CA861A6Q36347325-C113F638-8AED-4C80-B01A-D1BC41D80A37Q36908998-756B7282-48CF-4D1E-A59B-BD471EFF9B2BQ37038453-C3F57644-416B-439D-B3FA-B983327E8346Q37189622-394A4E4A-A994-4412-AA58-638154A06E53Q37190754-B4A85D24-4256-45EC-9FF4-4AD545A2C120Q37191559-910376FE-9662-4765-9131-21353B1E9F94Q37256389-A2F5E253-83A2-4629-92FB-E46D1EBCA590Q37268341-2D47838C-1899-4C93-AFC4-C85002415CBCQ37278724-04BDF38B-17BB-4DBB-8AE2-F5788DB1864FQ37314872-DBC598E6-0CAE-408A-8546-967B44D2DC83Q37661745-1EB82182-06E0-44BA-9041-9CACC4BDF953Q38209874-C6509D47-4DE2-43C6-A3EF-E13D492DB2EDQ41961412-8E4C4DFC-ABA9-4F41-8720-8EAEB18E3608Q43172779-033AE21A-CF97-4E7F-951D-FAC0DB2383E0Q54695288-616BD062-12FA-4ABF-9B88-4F195CDC2D69Q57708705-026789E8-196C-4021-9A2B-215E7DC38266Q57708766-AE7A887F-A491-48F3-9D8F-A3839ED998E4Q58485636-09ADB1E9-4EEB-40F0-BA0C-5C778CC96600
P2860
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
French national sentinel surve ...... nfected patients in 2001-2002.
@en
French national sentinel surve ...... nfected patients in 2001-2002.
@nl
type
label
French national sentinel surve ...... nfected patients in 2001-2002.
@en
French national sentinel surve ...... nfected patients in 2001-2002.
@nl
prefLabel
French national sentinel surve ...... nfected patients in 2001-2002.
@en
French national sentinel surve ...... nfected patients in 2001-2002.
@nl
P2093
P50
P1476
French national sentinel surve ...... nfected patients in 2001-2002.
@en
P2093
Anne Signori-Schmück
Annick Ruffault
Bernard Masquelier
Catherine Tamalet
Christiane Deveau
Cécile Poggi
Didier Ingrand
Evelyne Kohli
Françoise Brun-Vezinet
Isabelle Pellegrin
P304
P356
10.1097/01.QAI.0000155201.51232.2E
P407
P50
P577
2005-04-01T00:00:00Z